Eupraxia reports new odynophagia data from Phase 1b/2a RESOLVE trial in EoE
The company said swallowing pain and difficulty both dropped substantially in a subset of patients through 52 weeks, with no serious safety signals reported.
SEC filing
Latest
Thursday, August 13
MapLight enters $150M private placement agreement, reports Q2 2026 results
The company anticipates gross proceeds of about $150 million from investors and says cash should last through 2028 as it advances ML-007C-MA.
SEC filing
FDA approves Bristol Myers Squibb's Zenbexus, a new molecular entity
The agency granted priority review approval to iberdomide hydrochloride capsules for oral use, with an approval letter dated August 17, 2026.
Drugs@FDA
PTC Therapeutics wins bankruptcy auction for Sangamo's Fabry gene therapy ST-920
PTC agreed to pay $111 million upfront plus up to $100 million in milestones for the BLA-stage AAV gene therapy, with a rolling FDA submission targeted for the fourth quarter of 2026.
SEC filing
Assembly Bio reports Q2 2026 results, expands ABI-6250 into cholestatic liver disease
Company closed a $115 million financing and disclosed Gilead's plan to advance GS-1179 into Phase 2 for genital herpes by year-end 2026.
SEC filing
ADC Therapeutics reweighs ZYNLONTA path after FDA raises LOTIS-5 safety concerns
The company posted $18.6 million in Q2 2026 product revenue and $219.1 million in cash while evaluating next steps after an FDA pre-sBLA meeting flagged benefit-risk issues in the LOTIS-5 trial.
SEC filing
Aptevo closes $4.5 million warrant inducement and PIPE financing
The transactions, first announced August 12, 2026, closed August 13, 2026, with Roth Capital Partners as placement agent.
SEC filing
Atrium Therapeutics clears IND for ATR 1072, activates first Corventis sites for PRKAG2 syndrome
The company also banked a second $15 million Bristol Myers Squibb milestone and reported cash runway into mid-2028.
SEC filing
Madrigal registers pediatric Phase 2a trial of resmetirom for MASH
Pyxis Oncology reaffirms MICVO data timelines, closes $50 million private placement
Updated monotherapy data are still expected this fall and combination data in Q4 2026, after a financing extended cash runway into Q2 2027.
SEC filing
MeiraGTx reports Q2 2026 results, advances bota-vec and AAV2-hAQP1 toward filings
The company completed the bota-vec acquisition from J&J, finished enrollment in its pivotal AQUAx2 study, and secured up to $400 million from Oberland Capital.
SEC filing
AbbVie posts Crohn's OLE results; registers Phase 3 lung cancer and Phase 1 glabellar lines trials
BMS posts JAKARTA Phase 3 results, updates Opdivo label, registers golcadomide renal study
ProQR reports Q2 2026 results, cites first Axiomer clinical validation from AX-0810 data
ProQR raised $59.2 million and ended the quarter with €117.1 million in cash, extending runway into mid-2028 as it awaits further Axiomer pipeline data.
SEC filing
Tempest Therapeutics signs up to $50 million stock purchase deal with Lincoln Park Capital
The August 13, 2026 agreement lets Tempest sell shares to Lincoln Park in stages over up to 24 months, subject to conditions and price limits.
SEC filing
MacroGenics reports Q2, streamlines model, updates ADC and bispecific pipeline
MacroGenics paired second-quarter results with a completed manufacturing divestiture and fresh pipeline updates, including a Gilead option exercise and ESMO data plans.
SEC filing
Parabilis reports Q2 2026 results, $1.1B cash, Regeneron pact
The company posted a $52.5 million quarterly net loss while advancing zolucatetide toward a planned Phase 3 desmoid tumor trial and detailing a new Regeneron collaboration.
SEC filing
Ascendis Pharma posts Q2 2026 revenue of €315 million, up 105% year over year
Growth was driven by YORVIPATH and a new YUVIWEL launch, while a PRV sale and note conversion reshaped the balance sheet.
SEC filing
Humacyte registers two Symvess trials: adolescent Phase 3 study and adult Phase 4 real-world study
Wednesday, August 12
Connect Biopharma finishes enrollment in Phase 2 asthma, COPD exacerbation studies
The company expects topline data from both Seabreeze STAT trials of rademikibart in September 2026 and plans to meet the FDA afterward on a Phase 3 program.
SEC filing
BioStem Technologies posts Q2 2026 revenue growth, completes Nasdaq uplisting
BioStem reported $7.9 million in second-quarter revenue, raised full-year guidance, and uplisted to the Nasdaq Capital Market on August 7, 2026.
SEC filing
Unicycive says FDA has assigned facility inspection for OLC manufacturing vendor
The company expects to resubmit its NDA for oxylanthanum carbonate once the third-party manufacturing inspection is completed successfully.
SEC filing
Cypherpunk's Leap Therapeutics subsidiary aligns with FDA on Phase 3 trial for sirexatamab
Leap says the FDA backed a dual-endpoint Phase 3 design in DKK1-high colorectal cancer as parent Cypherpunk reports a $46 million unrealized gain on its Zcash treasury.
SEC filing
Inovio's INO-3107 BLA review advances toward October 30 PDUFA date
Inovio said the FDA has not yet weighed in on accelerated approval eligibility for INO-3107 but expects feedback on the confirmatory trial design, as it reported second-quarter 2026 results.
SEC filing
Altimmune reports Q2 2026 results as pemvidutide advances in MASH, AUD and ALD
The company started its Phase 3 MASH trial, posted positive Phase 2 alcohol use disorder data, finished enrollment in a liver disease trial and held $519 million in cash and investments.
SEC filing
Minerva Neurosciences names Anthony Aliquo chief accounting officer
The board's move on August 10, 2026 shifts principal accounting officer duties away from CFO Fred Ahlholm, who stays on as finance chief.
SEC filing
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026
The company reported majority share of new patient starts in its menin inhibitor class and $519 million in cash to fund the ziftomenib program toward 2028 Phase 3 results.
SEC filing
Paterna BioSciences HoldCo discloses Form D equity offering of $11.2 million
The Salt Lake City biotechnology company reported $6.3 million sold to 17 investors as of a July 30, 2026 first sale date, according to an SEC filing signed August 12, 2026.
SEC filing
Vogenx registers Phase 2b trial of mizagliflozin for post-bariatric hypoglycemia
Silence Therapeutics prices $175 million ADS offering at $13.50 per share
The siRNA drugmaker priced 12,962,963 ADSs on August 11, 2026, with the offering expected to close August 13.
SEC filing (3)
Dyadic reports Q2 2026 results, cites commercial and C1 platform progress
The company disclosed a going-concern doubt alongside quarterly shipments, OEM and partner sales activity, and continued Gates Foundation and CEPI-backed antibody and vaccine antigen work.
SEC filing
Journey Medical reports Q2 2026 results as Emrosi prescriptions climb
The dermatology company posted 23% revenue growth and narrowed its net loss as Emrosi prescriptions rose for a second straight quarter.
SEC filing
First Tracks reports Q2 2026 results, ANB033 gets FDA Fast Track in celiac disease
The company finished enrollment in a gluten-challenge cohort of its Phase 1b celiac trial and expanded a second cohort, while reiterating a cash runway into Q2 2028.
SEC filing
Trace Biosciences files Form D covering $16.2 million equity offering
The Delaware biotech, based in Beaverton, Oregon, disclosed it has sold about half of a planned equity raise from 19 investors.
SEC filing
AEON Biopharma reports Q2 2026 results, cites new financing and FDA meeting on ABP-450
The company reported cash of $3.4 million as of June 30, 2026, plus a July financing that it says extends its runway into early 2027 as it awaits further FDA feedback on its Botox biosimilar.
SEC filing
Acrivon reports Q2 2026 results, flags ACR-368 interim data for second half of 2026
Acrivon says its Phase 2b interim analysis in serous endometrial cancer is on track for the second half of 2026 as ACR-2316 moves into randomized dose expansion.
SEC filing
Citius Oncology adds Jonathan Peri to board, expanding to nine members
The oncology-focused company, majority owned by Citius Pharmaceuticals, named the higher education and legal executive an independent director effective August 10, 2026.
SEC filing
Atara reports FDA meeting progress on tabelecleucel BLA resubmission, trims costs
Atara said it met with FDA on a path to resubmit the tabelecleucel BLA using existing Phase 3 data, while cutting quarterly costs 87% year over year.
SEC filing
PolyPid reports Q2 2026 results, FDA priority review for D-PLEX100
FDA accepted PolyPid's NDA with priority review, moving the PDUFA date to November 28, 2026, and the company banked $30 million from a new Azurity partnership.
SEC filing
Monopar starts rolling NDA for Wilson disease drug ALXN1840, reports Q2 2026 results
The company said it began a rolling FDA submission for ALXN1840 in July, backed by Rare Pediatric Disease designation and new Phase 3 data, with cash of $134.3 million.
SEC filing
Boehringer adds cardiac safety trial for verducatib alongside survodutide diabetes study
Annexon reports Q2 2026 results, sets tanruprubart BLA for fourth quarter
Annexon says early GBS trial data support a planned BLA filing this quarter, while its geographic atrophy program adds a Month 24 endpoint and a $200 million credit facility extends cash runway into 2028.
SEC filing
Spruce Biosciences targets Q4 2026 BLA filing for TA-ERT in MPS IIIB
The company also plans to start a required confirmatory trial in the fourth quarter and reported $96.3 million in cash as of June 30, 2026.
SEC filing
Apnimed posts Phase 2 MARIPOSA results showing AD109 cut AHI4 versus placebo
Allogene reports Q2 2026 results, cites ALPHA3 futility data and FDA designations for cema-cel
The company said an interim futility analysis in its Phase 2 ALPHA3 trial supported cema-cel's use in first-line LBCL, and the FDA granted RMAT and Fast Track status after reviewing that data.
SEC filing
Atea reports Q2 2026 results, cites C-BEYOND Phase 3 win in hepatitis C
Atea's HCV combination met its primary endpoint against Epclusa, and the company plans to file for FDA approval in the second quarter of 2027.
SEC filing
Avalyn completes enrollment in Phase 2b pulmonary fibrosis trial of AP01
The company reported topline data expected in the second half of 2027 and cash runway into 2029 as of its second-quarter 2026 results.
SEC filing
Spero reports Q2 2026 results, highlights Utebzi approval and Innovent license for SP001
Spero says FDA approval of Utebzi, a $105 million royalty financing, and an exclusive license for SP001 extend its cash runway into the second half of 2029.
SEC filing
argenx posts ADAPT SERON Phase 3 results; registers new Phase 2 in Sjögren's neuropathy
Turn Therapeutics expands Phase 2 atopic dermatitis trial after interim data review
Interim results led the company to broaden Stage 2 enrollment criteria while keeping the trial on track for year-end 2026 completion.
SEC filing